Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three selective serotonin reuptake inhibitors (SSRIs): escitalopram, paroxetine, and sertraline. Each of these medications works by inhibiting the reuptake of serotonin in the brain, though they have different pharmacological profiles and side effect patterns. Escitalopram is an allosteric serotonin reuptake inhibitor (ASRI) with well-documented allosteric properties at the serotonin transporter (SERT). Paroxetine has cholinergic muscarinic antagonism and potent inhibition of CYP2D6. Sertraline has dopamine transporter (DAT) inhibitory properties and moderate drug-drug interaction issues. These medications are typically prescribed individually rather than in combination for treating depression, anxiety disorders, and other mood disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on escitalopram + paroxetine + sertraline.